dmp 450 has been researched along with saquinavir in 3 studies
| Studies (dmp 450) | Trials (dmp 450) | Recent Studies (post-2010) (dmp 450) | Studies (saquinavir) | Trials (saquinavir) | Recent Studies (post-2010) (saquinavir) |
|---|---|---|---|---|---|
| 23 | 0 | 1 | 1,454 | 256 | 219 |
| Protein | Taxonomy | dmp 450 (IC50) | saquinavir (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 1.9 | |
| Bile salt export pump | Homo sapiens (human) | 3.9 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.016 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 0.0084 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.0131 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.05 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.5 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0066 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 4.273 | |
| Substance-K receptor | Homo sapiens (human) | 6.214 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.182 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 4.273 | |
| Mu-type opioid receptor | Homo sapiens (human) | 9.625 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 6.951 | |
| Exoribonuclease H | Human immunodeficiency virus 2 | 0.0005 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 1.9 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 1.9 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 1.9 | |
| Genome polyprotein | Human rhinovirus sp. | 0.0005 | |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | 8.26 | |
| Protease | Human immunodeficiency virus 1 | 0.0217 | |
| Protease | Human immunodeficiency virus 1 | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ala, P; Anton, ED; Bacheler, LT; Chang, CH; Garber, SS; Jadhav, PK; Woerner, FJ | 1 |
| Cheatham, WW; Dax, S; Wilkerson, WW | 1 |
| Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR | 1 |
3 other study(ies) available for dmp 450 and saquinavir
| Article | Year |
|---|---|
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Topics: Amides; Anti-HIV Agents; Cells, Cultured; Crystallography, X-Ray; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Protein Conformation; Sensitivity and Specificity; Urea | 1997 |
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
Topics: Anti-HIV Agents; HIV Protease Inhibitors; RNA, Viral; Structure-Activity Relationship; Urea | 1997 |
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication | 1998 |